Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03606642 · ClinicalTrials.gov registry record · Phase 2
SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance and Dual Anti-Platelet Therapy
A Phase 2 study, sponsored by HonorHealth Research Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT03606642 is a Phase 2 study that was terminated before completion, run by HonorHealth Research Institute. The registered enrollment target is 50 participants.
The verdict
NCT03606642, a Phase 2 study, was terminated before completion, sponsored by HonorHealth Research Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this study is to see if one month of dual antiplatelet therapy (DAPT) combined with the placement of the Synergy® Stent with IVUS (intravascular ultrasound) is safe for patients who are at high risk of bleeding (HBR).
Interventions
- DRUG Dual Antiplatelet (DAPT) Therapy
- DEVICE The Synergy® stent
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2018-11-19 |
| Est. Completion | 2022-08-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03606642
The ClinicalTrials.gov registry entry for NCT03606642 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is HonorHealth Research Institute, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dual Antiplatelet (DAPT) Therapy is the first listed.
NCT03606642 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03606642 about?
NCT03606642 is a clinical study titled "SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance and Dual Anti-Platelet Therapy". The purpose of this study is to see if one month of dual antiplatelet therapy (DAPT) combined with the placement of the Synergy® Stent with IVUS (intravascular ultrasound) is safe for patients who are at high risk of bleeding (HBR).
What is the current status of trial NCT03606642?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2018-11-19. Estimated completion is 2022-08-08.
What interventions are being tested in trial NCT03606642?
The interventions under investigation include: Dual Antiplatelet (DAPT) Therapy (DRUG), The Synergy® stent (DEVICE).
Who is sponsoring clinical trial NCT03606642?
This trial is sponsored by HonorHealth Research Institute, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.